인쇄하기
취소

Factive wins additional indication of multidrug-resistant streptococcus pneumoniae

Published: 2003-08-07 06:57:00
Updated: 2003-08-07 06:57:00
GeneSoft, which owns all the marketing and regulatory approval rights of LG Life Sciences' Factive (gemifloxacin) in North America and Europe, announced on July 29 that the U.S. Food and Drug Administration has approved Factive for the treatment of multidrug-resistant streptococcus pneumoniae.

The additional approval of Factive is the first ever since GeneSoft obtained the three indications ...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.